Our Website Uses Cookies 


We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.


For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Christopher Chen is a special counsel in our Shanghai office. His practice covers a wide range of corporate transactions across multiple sectors, including the life sciences and hi-tech industries. He has extensive experience in representing Chinese and foreign companies in cross-border transactions including foreign direct investment, mergers and acquisitions, collaboration, licensing, and distribution arrangements.

Mr. Chen also provides general corporate advice to various multinational companies, and provides regulatory advice to healthcare companies with a focus on medical device and digital health related regulatory issues.

  • Represented AstraZeneca in connection with its strategic joint venture with the Chinese Future Industry Investment Fund (FIIF) to discover, develop, and commercialize potential new medicines.
  • Represented a multinational pharmaceutical company in connection with its exclusive license of rights to import, distribute and promote a legacy product in the respiratory area.
  • Represented AstraZeneca in connection with its acquisition of an option to acquire a cGMP biologics manufacturing facility in Wuxi, China from WuXi AppTec.
  • Represented JW Therapeutics in connection with its license and strategic alliance agreement with Juno Therapeutics for the exclusive China rights to certain CAR-T products.
  • Represented Indivior in connection with its sale of its rights related to the Suboxone tablet in China to Zhejiang Pukang Biotechnology Co., Ltd.
  • Represented Hangzhou Zhongmei Huadong Pharmaceutical, a subsidiary of Huadong Medicine – an exclusive license of rights to develop and commercialize vTv Therapeutics LLC's GLP-1r agonist diabetes program in China and other Pacific Rim countries for upfront and milestone payments of up to $83 million.
  • Represented a multinational pharmaceutical company in connection with its acquisition of an option agreement to acquire a China-based biotech company with an IND-stage NCE compound in immune-oncology area, in conjunction with a collaboration agreement governing the period before the option exercise.
  • Represented Origin Technologies Corporation, LLC in connection with its $1.8 billion bid for Affymetrix, Inc.
  • Represented Tencent Holdings in its acquisition of a majority stake SuperCell Oy for $8.6 billion.
  • Represented a private equity firm in a potential acquisition in electronic industry involving substantial PRC entities and assets.
  • Represented a Singapore-based private equity fund in acquiring a Chinese internet content provider for purpose of overseas listing.
  • Represented a Netherlands-based gas operation company in acquiring the Chinese subsidiaries of a UK public company.
  • Represented a Japan-based manufacturer in a tender offer against a Chinese listing company.

Pro Bono

  • Represents a U.S. based charity fund in providing certain free surgeries for children from rural and poor families in China.
  • Represented a U.S. based charity fund in its financing poverty solution projects by cooperating with PRC domestic small-scale loan companies through P2P structure.

Previous Experience

  • U.S. Securities and Exchange Commission, Intern (2012)